Elevation of serum soluble vascular cell adhesion molecule-1 (sVCAM-1) levels in bronchial asthma

Abstract

We have previously shown the elevation of serum soluble intercellular adhesion molecule‐1 (sICAM‐1) and soluble E‐selectin (sE‐selectin) in patients with bronchial asthma during asthma attacks. In the present study, we extended our earlier study by measuring serum sVCAM‐1 levels by ELISA in 45 patients with bronchial asthma (23 atopic and 22 non‐atopic) during asthma attacks and in stable conditions in order to assess further the state of adhesion molecules in allergic inflammation of bronchial asthma. The levels of sVCAM‐1 in sera obtained during bronchial asthma attacks were higher than those in sera obtained in stable conditions. These findings were observed regardless of atopic status. To examine the regulatory mechanism in the elevation of serum sVCAM‐1 levels, serum tumour necrosis factor‐alpha (TNF‐α) levels were measured by ELISA. TNF‐α levels in sera obtained during bronchial asthma attacks were higher than those in sera obtained in stable conditions. The nature of change in serum TNF‐α levels correlated with the nature of change in serum sVCAM‐1 levels, but serum TNF‐α levels did not correlate with serum sVCAM‐1 levels. These results suggest that higher levels of sVCAM‐1 during asthma attacks may reflect the up‐regulation of VCAM‐1 expression in allergic inflammation, and that a soluble form of VCAM‐1 molecules may be useful markers for the presence of allergic inflammation. TNF‐α is shown to enhance the expression and release of VCAM‐1 in vitro, however; the regulatory mechanism in the elevation of serum sVCAM‐1 levels remains to be clarified.